Company Overview
Aethlon Medical develops immunotherapeutic technologies to combat infectious disease and cancer. To augment the body's natural immune defenses, the Aethlon Hemopurifier® reduces the presence of circulating viruses in infected individuals. The technology provides a first-line candidate defense against viruses that are not addressed with proven drug therapies, including natural occurring pandemic threats and agents of bioterrorism. The Hemopurifier® can also be deployed as a strategy to improve the benefit of approved antiviral drug regimens. At present, the Hemopurifier® is being advanced in the United States under an FDA approved clinical study. Aethlon Medical is also investigating the potential use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients. Aethlon Medical is also the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE). ESI's TauSome™ biomarker is being clinically evaluated as the basis for a blood-based test to identify CTE in living individuals.

Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update
Feb 14 2022, 4:15 PM EST

Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 14, 2022
Jan 31 2022, 8:01 AM EST

Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update
Nov 9 2021, 4:15 PM EST

Stock Overview
Symbol: AEMD
Exchange: Nasdaq
Market Cap: 21.86m
Last Price: $1.42
52-Week: $1.32 - $12.49

Investor Relations
S. A. Noonan Communications
Susan Noonan
susan@sanoonan.com

Management Team
Charles J. Fisher, Jr., M.D.
Chief Executive Officer and Director

James B. Frakes
Chief Financial Officer and Senior Vice President – Finance

Steven LaRosa, M.D.
Chief Medical Officer

Guy Cipriani
Senior Vice President and Chief Business Officer

Thomas L. Taccini
Vice President, Manufacturing and Product Development

Aethlon Medical, Inc.
11555 Sorrento Valley Road
Suite 203
San Diego, CA 92121

Disclaimer
Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.